Remove BioTech Remove Life Science Remove Patient Experience Remove Pharmaceuticals
article thumbnail

EVERSANA Completes Integration of Healthware Group and Strengthens Its Global Agency Network EVERSANA INTOUCH With Addition of New Full-Service Affiliate

Digital Health Global

EVERSANA INTOUCH Healthware joins five full-service affiliates and four specialty affiliates serving clients across the globe with world-class strategy, next-generation branding and creative, and innovative solutions to propel the future of life science marketing. They are, however, fully owned and operated by EVERSANA.

article thumbnail

Tools for Paying Medical Bills Don’t Help Health Consumers Manage Their Financial Health

Health Populi

There’s a gap between the supply of digital health tools that hospitals and health systems offer patients, and what patients-as-consumers need for overall health and wellbeing. This chasm is illustrated in The future of the digital patient experience , the latest report from HIMSS and the Center for Connected Medicine (CCM).

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Let’s Save the Date and Make Patient Engagement Official in 2022

Society for Participatory Medicine

Healthcare stakeholders such as health systems, pharmaceutical companies, biotech and life sciences firms, and insurance companies serve patients as end users. However, we are still missing the mark with patient involvement to make durable healthcare change towards a culture of patient centricity.

BioTech 107
article thumbnail

Pharma’s Future Relevance Depends on Empathy, Messaging, Partnering, and Supporting Patients and Providers

Health Populi

Top-line, Accenture points to four pillars on which the pharma industry can “reinvent its relevance,” as the report title suggests: To express greater empathy, understanding the patient experience of delaying treatment, financial impacts, and mental health challenges the pandemic has caused.

article thumbnail

Most Americans Across Party ID Favor U.S. Government Negotiation to Lower Rx Drug Costs

Health Populi

That would be profits made by pharmaceutical companies, cited by 80% of respondents. Ironic that in this Congressional session, pharmaceutical manufacturers are testifying about the life-saving benefits of their products, but priced to drive about one-third of Americans not to adopt them. consumers were asked.